Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
@article{ATM39887, author = {Mary E. Westerman and Christopher G. Wood}, title = {Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study}, journal = {Annals of Translational Medicine}, volume = {8}, number = {16}, year = {2020}, keywords = {}, abstract = {}, issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/39887} }